NCT02057783 Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension
| NCT ID | NCT02057783 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AGIR à Dom |
| Condition | Hypertension, Resistant to Conventional Therapy |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2015-03-26 |
| Primary Completion | 2025-02-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2015-03-26 with a primary completion date of 2025-02-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigators hypothesize that CPAP treatment for suppressing OSAS in combination with a physical activity program will optimize 24-hour blood pressure control in patients with OSA-related resistant hypertension.
Eligibility Criteria
Inclusion Criteria: * Patient with an obstructive sleep apnea (apnea-hypopnea index \> or equal to 15) * Patient with resistant hypertension uncontrolled by 3 or more antihypertensive agents * Ambulatory patient Exclusion Criteria: * Acute hepatic failure, biliary cirrhosis, cholestasis * Acute hypertension (SBP\>= 180 mmHg and/or DBP \>= 110 mmHg) * Contraindication to CPAP treatment
Contact & Investigator
Jean-Louis Pépin, Pr MD PhD
✉ JPepin@chu-grenoble.frJean-Louis Pépin, Pr MD PhD
PRINCIPAL INVESTIGATOR
Laboratoire EFCR, CHU de Grenoble, 38043, Grenoble, France
Frequently Asked Questions
Who can join the NCT02057783 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hypertension, Resistant to Conventional Therapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02057783 currently recruiting?
Yes, NCT02057783 is actively recruiting participants. Contact the research team at JPepin@chu-grenoble.fr for enrollment information.
Where is the NCT02057783 trial being conducted?
This trial is being conducted at Québec, Canada, La Tronche, France, Toulouse, France, Geneva, Switzerland and 1 additional location.
Who is sponsoring the NCT02057783 clinical trial?
NCT02057783 is sponsored by AGIR à Dom. The principal investigator is Jean-Louis Pépin, Pr MD PhD at Laboratoire EFCR, CHU de Grenoble, 38043, Grenoble, France. The trial plans to enroll 100 participants.